Figure 1. CONSORT Diagram for Patients Who Entered BREEZE-AD3 as Responders or Partial Responders.

Patients who had a validated Investigator Global Assessment for Atopic Dermatitis score of 0 or 1 were considered responders; those with a score of 2 were considered partial responders. No rescue therapy was used in these groups during the originating study (BREEZE-AD1/BREEZE-AD2).

^aFor baricitinib, 4 mg, the other reason was the investigator’s decision owing to the patient’s work commitments.